|
 |
| home > epc > winter 2002 > the outlook for central nervous system drug development |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
t is estimated that as many as 1.5 billion people worldwide are suffering at any given time from some type of central nervous system (CNS) disorder and therefore there is a strong demand from patients for effective treatments (1). In 2001, global sales of CNS products reached US$43 billion, an increase of 17% over the previous year (2). This represented the highest increase of all the top therapeutic categories (2). Pharmaceutical companies have taken note of the demand for CNS medicines and have invested heavily in this area. However, progress in developing new treatments for these complex disorders is dependent on identifying the relevant factors to each disorder and many of these disorders are still poorly understood (1).
The Health Burden of CNS Disorders
Studies by the World Health Organization (WHO) have shown that the impact of CNS disorders on society has been seriously underestimated by traditional health care approaches, as these focused on deaths and not disability (1, 3). In the 1990s, WHO global figures revealed that CNS conditions accounted for 28% of all years lived with a disability (YLDs) compared with 1.4% of all deaths and 1.1% of years of life lost (1, 3). The predominance of these conditions is not just restricted to the most developed countries and therefore there is a global demand for effective medicines treating CNS disorders.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Faiz Kermani, Budgets, Proposals and Marketing Executive, and Stuart McGuire, Business Development Executive at Chiltern International
Dr Faiz Kermani currently works in Business Development at Chiltern International, a CRO, where his role covers bids, proposals and marketing. Previously, Faiz worked in Business Development at CMR International, examining R&D productivity issues for pharmaceutical industry clients. He has also worked as a research analyst for Danish health care consultancy Informedica A/S, focusing on global pharmaceutical pricing and parallel importation.
He holds a PhD in immunopharmacology from St. Thomas' Hospital in London and a First Class Honours Degree in Pharmacology with Toxicology from King's College, London. .
Stuart McGuire has worked as a Business Development Executive at Chiltern International for two years.
After graduating in Chemistry from the University of Surrey in 1999, he worked in malaria research before moving into marketing. One of Stuart's current areas of interest at Chiltern is R&D within the Japanese pharmaceutical industry.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
